Search details
1.
Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study.
Cancer
; 130(6): 886-900, 2024 03 15.
Article
in English
| MEDLINE | ID: mdl-37960969
2.
Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 24(12): 1423-1433, 2023 Dec.
Article
in English
| MEDLINE | ID: mdl-37944541
3.
Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study.
Br J Haematol
; 185(3): 492-502, 2019 05.
Article
in English
| MEDLINE | ID: mdl-30828799
4.
Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis.
Haematologica
; 104(5): e211-e214, 2019 05.
Article
in English
| MEDLINE | ID: mdl-30442728
5.
Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts.
J Clin Oncol
; 41(3): 541-554, 2023 01 20.
Article
in English
| MEDLINE | ID: mdl-35763708
6.
Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma.
Clin Lymphoma Myeloma Leuk
; 23(5): 385-393, 2023 05.
Article
in English
| MEDLINE | ID: mdl-36967244
7.
Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myeloma.
J Comp Eff Res
; 12(6): e220186, 2023 06.
Article
in English
| MEDLINE | ID: mdl-37114426
8.
Management of Fibroblast Growth Factor Inhibitor Treatment-emergent Adverse Events of Interest in Patients with Locally Advanced or Metastatic Urothelial Carcinoma.
Eur Urol Open Sci
; 50: 1-9, 2023 Apr.
Article
in English
| MEDLINE | ID: mdl-37101768
9.
Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study.
J Clin Oncol
; 41(21): 3689-3699, 2023 07 20.
Article
in English
| MEDLINE | ID: mdl-37279408
10.
Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study.
Leuk Lymphoma
; 63(10): 2383-2392, 2022 Oct.
Article
in English
| MEDLINE | ID: mdl-35730586
11.
Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma.
Clin Drug Investig
; 42(1): 29-41, 2022 Jan.
Article
in English
| MEDLINE | ID: mdl-34822128
12.
Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma.
EJHaem
; 3(1): 97-108, 2022 Feb.
Article
in English
| MEDLINE | ID: mdl-35846215
13.
Impact of clinical versus radiographic progression on clinical outcomes in metastatic castration-resistant prostate cancer.
ESMO Open
; 5(6): e000943, 2020 11.
Article
in English
| MEDLINE | ID: mdl-33184097
14.
Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up.
Hemasphere
; 6(5): e712, 2022 May.
Article
in English
| MEDLINE | ID: mdl-35441128
15.
Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study.
J Rheumatol
; 36(4): 736-42, 2009 Apr.
Article
in English
| MEDLINE | ID: mdl-19273451
Results
1 -
15
de 15
1
Next >
>>